Hubei Topgene Biotechnology Co., Ltd, a China-based biotechnology company, has entered into a partnership with Shanghai Genechem Co., Ltd to collaborate on integrated drug toxicological safety evaluation, clinical research translation projects, and resource allocation. The partnership aims to leverage the strengths of both companies to enhance drug development processes. Financial details of the agreement have not been disclosed.
Genechem’s Expertise and Business Scope
Founded in 2002, Genechem is known for its comprehensive platforms, including a virus tool platform, omics platform, and a new drug development and evaluation platform. The company’s business scope spans across various stages of drug development, from gene research and target discovery to target validation, new drug development, and evaluation.
Topgene’s CRO Services and Capabilities
Topgene, on the other hand, is a Contract Research Organization (CRO) specializing in new drug research and evaluation. Its services include the breeding of non-human primate experimental animals, animal models, and pharmacodynamic evaluation of human diseases. Additionally, Topgene offers pharmacokinetic research evaluation, drug toxicity research and safety evaluation, biological analysis, molecular imaging technology and analysis, and medical device testing.
Collaboration Goals and Scope
The partnership between Hubei Topgene and Shanghai Genechem is set to deepen their collective expertise in drug toxicological safety evaluation and clinical research implementation. By pooling their resources and expertise, the two companies aim to streamline the drug development process, from initial research to clinical trials, ultimately contributing to the advancement of new drug therapies.- Flcube.com
